The DOI matches its Crossref record.
Sertraline Treatment of Transition-Associated Anxiety and Agitation in Children with Autistic Disorder
Abstract
The intolerance of children with autistic disorder to changes in their routine or environment is well known, typically presenting with acute symptoms of anxiety, panic, irritability, or agitation. In a clinical sample of children (6-12 years old) with autistic disorder and transition-induced behavioral deterioration, 8 of 9 patients showed a clinically significant improvement in response to sertraline treatment. Only one child was taking concurrent psychotropic medication. Therapeutic doses were surprisingly low in all cases (25-50 mg daily), with a clinical response appearing generally in 2-8 weeks. Adverse effects were minimal (one child developed stomachaches), except for apparent sertraline-induced behavioral worsening in 2 children when their doses were raised to 75 mg daily. In 3 children, an initial satisfactory clinical response appeared to diminish after 3-7 months of treatment, despite steady or increased doses. In 6 patients, the beneficial effects persisted throughout the several-month follow-up period. Only four of the children's families were identified as having mood and/or anxiety disorders. This open-label study suggests that short-term sertraline treatment may reduce the behavioral reactions seen in association with situational transitions or environmental changes in children with autistic disorder, though the beneficial effect may be only temporary in some children. Our experience suggests that small doses of sertraline may be effective and that some children may require divided doses of sertraline during the day. Controlled studies are needed to determine the efficacy, safety, and pharmacokinetics of sertraline in treating this "need for sameness," both in short-term and long-term studies of children with autistic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
Depression in Persons with Autism: Implications for Research and Clinical Care
Ghaziuddin, M., Ghaziuddin, N., & Greden, J. (2002) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1016330802348 · Cited by 579
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Indah Winarni, T., Chonchaiya, W., Adams, E., Au, J., Mu, Y., Rivera, S. M., Nguyen, D. V., & Hagerman, R. J. (2012) · Autism Research and Treatment · doi:10.1155/2012/104317 · Cited by 52
Assessing the validity of current mouse genetic models of obsessive-compulsive disorder
Wang, L., Simpson, H. B., & Dulawa, S. C. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32832a80ad · Cited by 50
“OCD patients often present with comorbid psychiatric conditions including tic disorders such as Tourette’s syndrome (Leonard et al., 1992; Steingard et al., 1997; Nestadt et al., 2001), anxiety and affective disorders (Nestadt et al., 2001), the impulse control disorder trichotillomania (King et…”
BackgroundMcDougle, C. J., Thom, R. P., Ravichandran, C. T., Palumbo, M. L., Politte, L. C., Mullett, J. E., Keary, C. J., Erickson, C. A., Stigler, K. A., Mathieu-Frasier, L., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01295-4 · Cited by 31
“conducted an open-label study of sertraline in nine children with autistic disorder (ages 6–12 years old) that had “transition-induced behavioral deterioration” [7].”
BackgroundPsychopharmacology of Autism Spectrum Disorder
Siegel, M. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.006 · Cited by 27
Metadata
- Authors
- STEINGARD, R. J., ZIMNITZKY, B., DeMASO, D. R., BAUMAN, M. L., & BUCCI, J. P.
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1997-01
- Volume
- 7
- Issue
- 1
- Pages
- 9-15
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W1988453270
- Cited by
- 164
- References
- 0
- FWCI
- 3.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.